The development of CHAMP: a checklist for the appraisal of moderators and predictors by Hoorn, R.A. van et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/181568
 
 
 
Please be advised that this information was generated on 2018-04-11 and may be subject to
change.
RESEARCH ARTICLE Open Access
The development of CHAMP: a checklist for
the appraisal of moderators and predictors
Ralph van Hoorn1* , Marcia Tummers1, Andrew Booth2, Ansgar Gerhardus3, Eva Rehfuess4, Daniel Hind5,
Patrick M. Bossuyt6, Vivian Welch7, Thomas P. A. Debray8, Martin Underwood9, Pim Cuijpers10, Helena Kraemer11,
Gert Jan van der Wilt12 and Wietkse Kievit13
Abstract
Background: Personalized healthcare relies on the identification of factors explaining why individuals respond
differently to the same intervention. Analyses identifying such factors, so called predictors and moderators, have
their own set of assumptions and limitations which, when violated, can result in misleading claims, and incorrect
actions. The aim of this study was to develop a checklist for critically appraising the results of predictor and
moderator analyses by combining recommendations from published guidelines and experts in the field.
Methods: Candidate criteria for the checklist were retrieved through systematic searches of the literature. These
criteria were evaluated for appropriateness using a Delphi procedure. Two Delphi rounds yielded a pilot checklist,
which was tested on a set of papers included in a systematic review on reinforced home-based palliative care. The
results of the pilot informed a third Delphi round, which served to finalize the checklist.
Results: Forty-nine appraisal criteria were identified in the literature. Feedback was obtained from fourteen experts
from (bio)statistics, epidemiology and other associated fields elicited via three Delphi rounds. Additional feedback
from other researchers was collected in a pilot test. The final version of our checklist included seventeen criteria,
covering the design (e.g. a priori plausibility), analysis (e.g. use of interaction tests) and results (e.g. complete
reporting) of moderator and predictor analysis, together with the transferability of the results (e.g. clinical
importance). There are criteria both for individual papers and for bodies of evidence.
Conclusions: The proposed checklist can be used for critical appraisal of reported moderator and predictor effects,
as assessed in randomized or non-randomized studies using individual participant or aggregate data. This checklist
is accompanied by a user’s guide to facilitate implementation. Its future use across a wide variety of research
domains and study types will provide insights about its usability and feasibility.
Keywords: Moderator, Predictor, Quality assessment, Subgroup, Personalized health care, Evidence based medicine,
Delphi
Background
It is widely accepted that the evaluation of healthcare inter-
ventions should encompass not only overall effectiveness,
but also the identification of factors that may influence ef-
fectiveness in individual patients [1]. Individuals receiving
the same or a similar treatment may show widely differing
responses due to differences in treatment dosage or admin-
istration, or differences in patient-level characteristics such
as age and genetic makeup [2, 3]. Understanding of how
patient-level characteristics influence treatment effects may
increase the overall effectiveness of health technologies,
help to avoid adverse events, and enhance overall patient
satisfaction with the treatment(s) received [4–7]. In-
creasingly, it is recognized that substantial health
benefits may be obtained by paying attention to such
differences between individuals [8–10].
Over the past few decades, several methods have
been proposed for evaluating heterogeneity in treat-
ment response. These methods typically distinguish
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between predictors and moderators of treatment response
(Fig. 1) [11, 12].
Predictors are factors that are associated (either
directly or indirectly) with a patient’s outcome, re-
gardless of the intervention received. For instance,
older patients may exhibit relapses of a disease more
often than younger patients, making old age a pre-
dictor of relapses. Moderators are factors that allow
estimation of an effect for a specific intervention for
a group of patients with specific factors. The effect
is brought about by a specific interaction with the
intervention. This is the case when, for example, a
relapse of a disease is better controlled with one
treatment than with another, but the difference be-
tween treatments is smaller for younger patients. In
that case, age is a moderator of treatment effect. In
the literature, the terms ‘moderator’ and ‘predictor’
are occasionally used interchangeably (or other terms
are used to describe their effects, such as effect
modifier, determinant or interaction effect). Hence, it
is important that the user first identifies whether the
effect that is being appraised is actually a moderator,
a predictor or other effect (e.g. an intermediate effect
(mediator), or main effect).
In medical research, methods such as regression or
subgroup analyses are often employed to test hypotheses
concerning sources of heterogeneity. These methods can
be conducted as secondary analysis within individual tri-
als. Several assumptions and limitations are associated
with these methods [10, 11]. Violating these assumptions
and ignoring these limitations can result in question-
able claims concerning the validity of treatment effects
[13–16]. Critical appraisal is required before making
clinical or policy decisions based on such information.
Most guidance on literature appraisal is aimed at valu-
ing the primary outcome of a study; the overall validity,
methods and other study properties that determine the
relevance and credibility of the presented outcomes.
Although several guidance documents exist to help
researchers identify predictor and moderator variables
[15, 17–20], their usefulness is often limited as they gen-
erally presume the user has more in depth knowledge of
statistical methodologies. Moderator and predictor analyses
are different from analyses related to the main outcome in
multiple ways. They are more complicated, and since they
are based on subpopulation of the main study population,
they are associated with greater uncertainties. Existing
guidance documents on predictor and moderator variables
target specific study types (e.g. identification of effect mod-
ifiers in meta-analysis of published randomized trials) or
fail to justify or clarify how items are to be defined or used.
In addition, there is inconsistent usage of the “predictor”
and “moderator” terms, further complicating the identifica-
tion and critical appraisal of published intervention studies.
Aim
The aim of our study was to create a uniform checklist
for critically appraising the results of studies investigat-
ing factors of heterogeneity in treatment response. The
checklist should be applicable in both randomized and
non-randomized studies, and for both studies using indi-
vidual patient data as aggregated data. The resultant
checklist is intended for use in evaluating the validity of
claims in studies for inclusion in health technology as-
sessments, evaluating evidence for creating protocols in
health care or constructing an evidence base for system-
atic reviews. To our knowledge, this is the first checklist
to critically appraise reported moderators and predictors
of treatment effect, with respect to their credibility,
transferability and relevance for use.
Methods
This study was conducted as part of the INTEGRATE-
HTA project. INTEGRATE-HTA is an EU-funded project
(http://www.integrate-hta.eu/) which aims to further re-
fine methods of healthcare evaluation to take into account
complexity. The heterogeneity of patients resulting in
different treatment effects may be conceived as a source
of complexity [21].
Initial choices
In starting to develop the appraisal checklist, we defined
the following criteria:
 Users should first be encouraged to use existing
tools (see for instance those included in several
Intervention Outcome
Moderator
Intervention Outcome
Predictor
Fig. 1 Schematic overview of two models containing a simple relationship between an input variable (e.g. intervention), an output variable
(e.g. effect) and a predictor (left) or moderator (right)
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systematic reviews [22, 23]) to appraise the overall
risk of bias for the main effect in any given study.
Appraisal of the moderator/predictor analysis is only
to be pursued if the overall risk of bias is considered
acceptable, as a lack thereof precludes adequate
moderator/predictor analysis;
 The checklist should facilitate critical appraisal
regarding claims about moderators or predictors
described in a body of evidence, but also facilitate
critical appraisal of individual studies;
 The checklist should not yield a summary or
weighted score, as any weights would be arbitrary
and hard to justify [24, 25]. Instead, users are invited
to reach an overall, qualitative judgment in a
structured manner;
 The checklist should consist of closed questions,
with answering categories including ‘yes’, ‘no’, ‘don’t
know’ and ‘not applicable’. The third option allows
users to indicate that they do not consider
themselves sufficiently qualified to judge the relevant
item, or that the article does not report sufficient
information to answer the question, while the fourth
indicates that the item does not apply to the
moderator or predictor being appraised.
Procedure of checklist development
The development of the appraisal checklist consisted
of four steps: (1) systematic searches for existing lit-
erature on moderator and predictor analysis to iden-
tify candidate criteria; (2) a Delphi procedure to select
criteria that were considered most relevant for inclu-
sion in the checklist; (3) pilot testing of the draft
checklist; and (4) an evaluation of a modified checklist
in a final Delphi round.
Step 1: Literature search
PubMed and Google Scholar were searched to identify
candidate criteria for moderators and predictors of treat-
ment effect, relying on the assumption that these two
databases taken together cover most of the relevant litera-
ture in health and related fields. In PubMed, MeSH-terms
(e.g. “Effect modifier, Epidemiologic”, “Randomized Con-
trolled Trials as Topic”, “Moderators of treatment effects”,
“moderators”, “subgroup”, “heterogeneity” and combi-
nations thereof ) were combined with keywords relat-
ing to appraisal (e.g. “critical appraisal”, “appraisal”,
“guidance”, “methodology”, “quality assessment”). The
same set of keywords was used to search in Google
Scholar.
Key citations were identified and used to initiate add-
itional searches based on their keywords and MeSH-terms,
citation tracking and author searches. All search results
were scanned for possible relevant content based on title
and abstract (PubMed), or title and visible text snippets
(Google Scholar) by one author (RvH).
Based on the selection of relevant papers, a list of can-
didate criteria for either moderator or predictor analysis
was compiled. Duplicates were eliminated. Some criteria
were slightly rephrased to produce a uniform answering
format (e.g. transforming a statement into a polar question).
Criteria were then classified so that they mapped to specific
sections of a typical research article, thus improving the
usability of the checklist.
Step 2: Delphi procedure
Thirty-seven experts were invited to determine which cri-
teria of the list extracted in step 1 should be considered
appropriate for the checklist. The experts were identified
during the literature search and through our network, and
included epidemiologists and (bio)statisticians from sev-
eral European and North American countries.
A Delphi procedure was used to elicit the experts’
opinions in accordance with the Research ANd Develop-
ment (RAND) Appropriateness Method manual [26]. In
the first round, participants were asked to rate the ap-
propriateness of individual criteria for inclusion in the
checklist on an interval scale of 1 (not appropriate) to 9
(highly appropriate). Participants were also given the
opportunity to propose re-formulations or additional
criteria. In a second round, participants were asked to
rate the same criteria (including rewordings or additions),
excluding those criteria that had been agreed to be in-
cluded or excluded in the first round. For each round,
experts were invited by email and reminded up to two
times. The Delphi rounds were conducted through online
questionnaires.
Candidate criteria were removed from the list if an
agreed appropriateness score of <4 was reached in any
of the Delphi rounds according to the InterPercentile
Range Adjusted for Symmetry (IPRAS)-method [26].
Criteria were included if they scored >6 and agreement
had been reached according to the IPRAS method. The
remaining criteria were considered inconclusive. The
core research team from the INTEGRATE-HTA project
(RvH, WK, MT and GJvdW) was tasked with handling
the comments and suggested rewordings following each
round, as well as the implementation of decisions to
include or exclude appraisal criteria. Ultimately, the first
two Delphi rounds resulted in a test version of the
checklist containing the full set of consensual criteria.
Step 3: Pilot testing
The INTEGRATE-HTA project included a case-study
which was used to demonstrate the methods described
in the project [27]. Several researchers involved in this
project appraised a set of papers with a pilot version of
the checklist we named CHecklist for the Appraisal of
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Moderators and Predictors (CHAMP) (RvH, MT, WK,
AB, AG, and CL). This test set consisted of twenty-two
papers reporting on the effectiveness of reinforced
models of home-based palliative care. [28–49] Com-
ments and feedback were collected regarding the check-
list as a whole and on individual criteria (e.g. concerning
usability, clarity, or applicability). Furthermore, inter-
rater agreement on extracted scores was calculated to
determine whether the included criteria were used/inter-
preted similarly by different researchers. Subsequently,
the checklist was revised based on these results and
feedback from the researchers.
Step 4: Evaluation
In this final step, the new version of the checklist
was presented to two participants of the Delphi pro-
cedure for early, in-depth feedback on the revisions.
Based on their comments and feedback, adjustments
were made and the revised checklist was presented
(Delphi round 3) to the entire panel of experts who
had participated in the previous two rounds of the
Delphi procedure. The panel was asked whether they
agreed with the content, form and design of the
checklist, and was given the option of providing additional
comments. Based on these comments, the checklist was
finalized.
Results
Step 1: Literature search
During the literature search, five articles were identified as
key citations [14, 15, 17, 50, 51]. These citations were used
to further grow the number of search terms and to initiate
citation chasing (forward/backward citation searches).
Ultimately, forty-nine candidate criteria were identified for
the appraisal of moderator/predictor analyses. As some of
the criteria applied to a body of evidence (i.e. a systematic
review or multiple related studies), these criteria were
grouped in a separate category. Additional file 1 presents
the complete list of criteria, their origin and changes
throughout the development process of the checklist, as
well as testing phase feedback and statistics.
Figure 2 is a flowchart of the entire procedure, outlin-
ing the number of appraisal criteria and experts involved
in each step of the development of the checklist.
Step 2: Delphi procedure
Delphi round 1
During the first Delphi round, the 49 criteria were rated
by 14 experts (37 invited). Based on their assigned scores
(mean score 6.9, range 6.1–8.1), 25 criteria were included.
There was insufficient agreement on the remaining 24 cri-
teria. Among these, five had a sufficient appropriate-
ness score (mean 6.9, range 6.3–7.3), and 19 had an
inconclusive appropriateness score (mean 5.3, range
Final version
Step 4b:
Delphi round 3 / evaluation (n=5 
participants)
Step 3 / 4a:
Pilot test / revision
Step 2b:
Delphi round 2 (n=12 participants)
Step 2a:
Delphi round 1 (n=14 participants)
Step 1:
Literature review
49 criteria 
identified in the 
literature
24 criteria 
evaluated in 
next round
15 excluded
(1 with agreement, 
14 by research team)
9 criteria agreed 
to be included
31 criteria in 
test -version of 
CHAMP
14 criteria 
removed due to 
overlap
17 criteria 
remained in 
CHAMP
17 criteria in 
CHAMP
25 criteria 
agreed to be 
included
22 criteria 
remained in 
checklist*
3 criteria 
removed due to 
overlap*
Fig. 2 Process of inclusion and exclusion of appraisal criteria throughout the development procedure
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4.6–5.9). These 24 criteria were re-evaluated in the
second Delphi round. Suggestions for rewording and
additional criteria were considered and changes made
if considered appropriate.
Delphi round 2
Of the 14 experts, 12 provided feedback during the sec-
ond Delphi round. Participants were also encouraged to
assess potential overlap between the remaining criteria.
Based on the results of this round, one criterion was
removed following general agreement on low appropri-
ateness (3.33). Seven criteria were selected for inclusion
in the checklist (mean 6.9, range 6.1–7.7). Fourteen cri-
teria were excluded based on low appropriateness and
negative feedback. The remaining two criteria, which
had appropriateness scores below the threshold but with
no agreement, were put forward to the test phase. Re-
phrasing of criteria was performed based on feedback.
This resulted in the merging of three criteria already ac-
cepted in round 1. At the end of the second Delphi
round, the checklist consisted of 31 criteria. Of these, 20
criteria were applicable to individual studies, eight to
systematic reviews and three to a set of related studies.
Step 3: Pilot testing
Six researchers tested the 20 criteria that were deemed
applicable to individual studies. This pilot checklist was
tested on individual studies including RCTs, observa-
tional/cohort studies and qualitative research. The cri-
teria intended to be used for systematic reviews and
multiple related studies could not be tested here, as no
systematic reviews or multiple related studies on rein-
forced models of home-based palliative care were found
to cover the same moderator/predictor. The inter-rater
agreement for most criteria included in the pilot test
was limited, mainly due to differences in interpretation
which resulted from insufficient clarification of single
criteria. For example, users indicated difficulties in inter-
preting phrases such as ‘in the case of hypothesis test-
ing’ (on what grounds should one decide whether this
condition is fulfilled), or ‘low number of hypotheses’
(expecting the checklist to describe a specific threshold).
None of the criteria was excluded in this round. Some
criteria were rephrased for improved ease of interpret-
ation. In addition, a user’s guide was compiled to clarify
how each criterion should be answered and to indicate
possible consequences if specific criteria were not met.
Step 4: Evaluation
Based on the feedback of two experts from the Delphi
panel, the criteria specific for systematic reviews and
the criteria addressing a body of evidence (n = 11) were
placed in the same category and rephrased into five
criteria covering a body of evidence. This step was
taken as most criteria concerning systematic reviews
were found to be interchangeable with those for mul-
tiple related studies. Due to overlap, another eight cri-
teria were removed or described under the explanation
of another criterion. This step resulted in a final version
of the checklist containing 17 criteria in total, of which
14 were unique. Three criteria were included twice
because they applied to individual studies as well as a
body of evidence.
Delphi round 3
Five of the original 14 participants responded to the
invitation for final feedback. A small number of adjust-
ments were made to improve the introduction of the
checklist and the user’s guide.
The final checklist
Table 1 lists the 17 criteria in the final version of the
checklist (Additional file 2). The final version also con-
tains a short introduction and definitions. Furthermore,
it contains references to appraisal checklists that might
be used to determine the overall quality of a study, to be
chosen at the users’ discretion. A guide is included, indi-
cating the type of information that the user should look
for within an article and explaining the rationale for each
criterion to allow the user to better estimate its impact.
Discussion
The product of this study is a checklist which can be
used to appraise claims concerning moderators or pre-
dictors in individual studies as well as bodies of evi-
dence. The checklist is envisioned to be used by authors
of systematic reviews investigating a specific (set of )
moderator or predictor effects, or by researchers who
need to identify relevant moderators or predictors to
consider for clinical decision making. The checklist can
be used by both experts and those less knowledgeable of
moderator or predictor analysis. The checklist may also
be used by journal editors and reviewers who aim to as-
sess the methodological quality of studies assessing a
moderator or predictor effect for a certain intervention.
The final version of the checklist consists of a set of
17 questions; 12 applicable to individual studies and 5
applicable to a body of evidence. The content of this
checklist is based on systematic searches of the literature,
a three-round Delphi procedure, and a pilot test to assess
the usability and any challenges associated with the use of
the checklist. In view of the rigorous development process,
we believe that the checklist is comprehensive, relevant
and acceptable as well as useable.
The checklist presented in this paper differs in several
aspects from previously reported checklists [15, 17].
First, our checklist has a wider scope of applicability.
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Previously published checklists focus on the appraisal of
subgroup analyses in trials, whereas our checklist also
covers other study types such as non-randomized studies
and systematic reviews. As moderators and predictors
can be identified through a broad range of study designs
and analyses, this is of special value in areas where trials
are not feasible.
Second, our checklist aims to help researchers to as-
sess the overall relevance of moderators or predictors
within clinical decision making or health technology as-
sessments. It therefore contains criteria aimed at asses-
sing transferability and comparison of effects across a
body of evidence and thus helps to obtain an overall
judgment not offered by previous checklists. All criteria
in the checklist are further described in a user’s guide,
facilitating use by those who lack specialized knowledge
of predictor or moderator analyses. Additional file 3
contains an overview of the most important differences
between our checklist and previous checklists.
A generic difficulty in developing and using appraisal
checklists lies in distinguishing between the quality of a
study and the quality of its reporting. Inevitably, a good
standard of reporting is required if one is to properly ap-
praise a moderator or predictor. For this reason, our
checklist also includes criteria that relate to reporting
quality (e.g. mentioning pre-specification of hypotheses).
Also, there may be a relation between good reporting
quality and good methodological quality. For instance, if
researchers are aware of the fact that predefined hypoth-
esis testing is important, they are likely to report this in
their article. Therefore, criteria that are not properly
reported are more likely to be of poor quality.
It should be noted that for several criteria within our
checklist, no general agreement currently exists on what
constitutes best practice. For instance, different statis-
tical methods exist for subgroup identification, [52–54]
but these are difficult to assess when researchers are not
familiar with them. Although we aimed to provide guid-
ance on these issues, it was difficult to provide strict
criteria or specific cut-off points. For this reason, we
recommend that any appraisal should involve a team
with complementary skills, including clinicians as well as
methodologists.
One limitation of the methods employed in our study lies
in the use of the RAND Appropriateness Method for the
selection of criteria. This means that the appropriateness of
any individual criterion is dependent on the inclusion of all
other criteria. In addition, the list of criteria is dynamic
due to the ability of participants to suggest rewordings
or additional criteria. Ideally, each change would re-
quire a reassessment of all criteria for appropriateness
until agreement is reached. However, given the different
backgrounds of the participants, valuations will not
always converge. The appropriateness method rarely
resulted in complete agreement on the exclusion of cri-
teria, leaving room for the core research team to make
final decisions. Ideally, the wording of criteria and the se-
lection of criteria would have been split into separate
phases. In spite of these limitations, there was broad
agreement among the experts on the final version of the
checklist, meaning that it appropriately reflects current
views on how the validity of claims regarding prediction
and moderation of treatment effects should be judged.
A second limitation is the fact that the Delphi panel
was relatively small. Even though we believe that it com-
prised the relevant range of expertise across several
countries, we may not have accommodated all available
Table 1 Questions in the checklist for assessing moderators and
predictors of treatment effects. Note that questions 10–12 are
listed also as questions 13–15, as they are applicable both to
individual studies and bodies of evidence covering the same
moderator or predictor
Criteria for individual studies
Design
1. A priori plausibility: was there sufficient empirical or theoretical
support for the moderator or predictor that was examined?
2. Was the moderator or predictor specified a priori?
3. Was the moderator or predictor variable measured before the
allocation or start of the intervention?
4. Was measurement of the moderator or predictor reliable and
valid in the target population?
Analysis
5. In case of a moderator, was an interaction test used?
6. Was a limited number of moderators and predictors tested?
7. Was sample size adequate for the moderator or predictor
analysis?
Results
8. Were results presented for all candidate moderators or predictors
that were examined?
9. Did statistical tests or confidence intervals indicate that observed
moderator or predictor effects were unlikely to be merely due to
chance variation?
10. Was the moderator or predictor effect consistent with related
moderators or predictors, or across related outcomes measured
within the study?
Transferability
11. Were the setting and study population comparable to the
setting and population in which the information would be
used?
12. Is the moderator or predictor effect clinically important?
Criteria for bodies of evidence (systematic review or related
sets of studies)
13. Was the moderator or predictor effect consistent with related
moderators or predictors, or across related outcomes measured
between the studies?
14. Were the setting and study population comparable to the
setting and population in which the information would be
used?
15. Is the moderator or predictor effect clinically important?
16. Was the moderator or predictor effect reasonably homogenous
across studies?
17. Was the moderator or predictor measured similarly across the
included studies, or was an adequate conversion performed?
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viewpoints. Although we performed a very extensive lit-
erature search, we may have missed articles, due to the
diversity and variability of the terminology used in per-
sonalized, stratified and precision healthcare. [55–57]
We do think the range of experts in our Delphi panel
was able to compensate for any possibly missed relevant
literature. Furthermore, the pilot test was relatively mod-
est in the number of articles on which the checklist was
piloted, so the future use of CHAMP will provide im-
portant additional insights regarding the usability of the
checklist and the implications of its use for how we
judge moderator and predictor findings.
Conclusion
An appraisal checklist was created to help researchers for-
mally appraise moderator or predictor analyses. The con-
tents of the checklist were based on literature, three Delphi
rounds and pilot testing. The use of such a checklist is rele-
vant as moderator and predictor analyses are becoming in-
creasingly common as the demand for personalized health
care is growing. The CHAMP checklist expands upon exist-
ing tools, providing coverage and clarification for appraisal
of randomized and non-randomized studies, as well as bod-
ies of evidence. We tested its feasibility in an extensive pilot
study. More experiences from different users and new de-
velopments in the future will allow a further refining and
improvement of CHAMP.
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Additional file 1: Contains the history of the criteria contained in the
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Additional file 2: Contains the product of this study, the CHAMP
checklist, including packground information. (PDF 510 kb)
Additional file 3: Contains a table with the comparison of our checklist
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